Response Evaluation Criteria in Solid Tumors
"Response Evaluation Criteria in Solid Tumors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An internationally recognized set of published rules used for evaluation of cancer treatment that define when tumors found in cancer patients improve, worsen, or remain stable during treatment. These criteria are based specifically on the response of the tumor(s) to treatment, and not on the overall health status of the patient resulting from treatment.
| Descriptor ID |
D066066
|
| MeSH Number(s) |
E01.789.800.379 N04.761.559.590.800.569 N05.715.360.575.575.800.569
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Response Evaluation Criteria in Solid Tumors".
Below are MeSH descriptors whose meaning is more specific than "Response Evaluation Criteria in Solid Tumors".
This graph shows the total number of publications written about "Response Evaluation Criteria in Solid Tumors" by people in this website by year, and whether "Response Evaluation Criteria in Solid Tumors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2015 | 0 | 1 | 1 |
| 2016 | 1 | 2 | 3 |
| 2017 | 0 | 5 | 5 |
| 2018 | 1 | 7 | 8 |
| 2019 | 1 | 5 | 6 |
| 2020 | 1 | 3 | 4 |
| 2021 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Response Evaluation Criteria in Solid Tumors" by people in Profiles.
-
Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial. Gynecol Oncol. 2021 08; 162(2):375-381.
-
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2021 06; 22(6):872-882.
-
Model Informed Dosing Regimen and Phase I Results of the Anti-PD-1 Antibody Budigalimab (ABBV-181). Clin Transl Sci. 2021 01; 14(1):277-287.
-
Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors. J Clin Oncol. 2020 11 01; 38(31):3672-3684.
-
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020 10; 21(10):1353-1365.
-
Association between end-induction response according to the revised International Neuroblastoma Response Criteria (INRC) and outcome in high-risk neuroblastoma patients. Pediatr Blood Cancer. 2020 10; 67(10):e28390.
-
Response Criteria for Intratumoral Immunotherapy in Solid Tumors: itRECIST. J Clin Oncol. 2020 08 10; 38(23):2667-2676.
-
Response rates in metastatic neuroendocrine tumors receiving peptide receptor radionuclide therapy and implications for future treatment strategies. Surgery. 2021 01; 169(1):162-167.
-
Optimization of response classification criteria for patients with malignant pleural mesothelioma, a validation study. Lung Cancer. 2019 12; 138:139-140.
-
Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer. Lung Cancer. 2019 11; 137:38-42.